SFJ has successfully completed two clinical programs and is currently managing four global phase III oncology clinical trials across multiple therapeutic indications. Additional programs are currently under negotiation and will be added to this page as appropriate. To date, SFJ has invested over $550M in ongoing collaborations and has more than $1.5B available for future collaborations.